## STE: STERIS plc (Ireland) - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.8% below STRENGTH zone (4.0-10.0%); PEG 1.84 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($247.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. STERIS plc (NYSE:STE) Given Consensus Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251209T070237 | Bullish | Relevance: 99%
- Nine brokerages have given STERIS plc (NYSE:STE) a consensus "Moderate Buy" rating, with an average one-year target price of $273.50. The company recently surpassed Q1 earnings expectations, reporting an EPS of $2.47 against estimated $2.38, and revenue of $1.46 billion versus $1.43 billion. STERIS also announced a quarterly dividend of $0.63, while institutional investors hold approximately 94.7% of its stock.

**2. iSAM Funds UK Ltd Acquires Shares of 8,433 STERIS plc $STE**
- Source: MarketBeat | 20251209T135600 | Somewhat-Bullish | Relevance: 99%
-  iSAM Funds UK Ltd acquired 8,433 shares of STERIS plc, valued at approximately $2.03 million, during the second quarter. STERIS outperformed earnings expectations, reporting an EPS of $2.47 against an estimated $2.38, and announced a quarterly dividend of $0.63 per share. Despite positive financial results, company insiders have been net sellers, divesting 25,203 shares over the last 90 days.

**3. 1832 Asset Management L.P. Takes Position in STERIS plc $STE**
- Source: MarketBeat | 20251207T081758 | Somewhat-Bullish | Relevance: 98%
-  1832 Asset Management L.P. has acquired a new stake in STERIS plc (NYSE:STE), purchasing 9,832 shares valued at approximately $2.36 million. This move is part of broader institutional investor activity, with other major firms like Vanguard Group Inc. and Generation Investment Management LLP also adjusting their positions in the medical equipment provider. STERIS has received a "Moderate Buy" rating from analysts with an average target price of $273.50, and the company recently announced a quarterly dividend.

**4. WINTON GROUP Ltd Takes Position in STERIS plc $STE**
- Source: MarketBeat | 20251209T141537 | Somewhat-Bullish | Relevance: 98%
-  WINTON GROUP Ltd initiated a new position in STERIS plc (NYSE:STE) during the second quarter, acquiring 13,215 shares valued at approximately $3.18 million. Institutional investors collectively own about 94.69% of the medical equipment provider's stock, while company insiders have recently been net sellers, divesting 25,203 shares worth about $6.62 million. STERIS reported strong quarterly earnings, beating expectations with an EPS of $2.47 and revenue of $1.46 billion, and announced a quarterly dividend of $0.63.

**5. Thematics Asset Management Trims Stock Position in STERIS plc $STE**
- Source: MarketBeat | 20251208T121541 | Somewhat-Bullish | Relevance: 97%
-  Thematics Asset Management reduced its stake in STERIS plc (NYSE:STE) by 24.6% in the second quarter, selling 36,885 shares and now holding 113,249 shares valued at $27.21 million. Despite this trimming, other institutional investors like Orbis Allan Gray and Norges Bank initiated significant new positions, and UBS AM and Invesco Ltd. materially increased their stakes. STERIS reported a strong EPS beat for the last quarter and provided positive FY2026 guidance, alongside announcing a quarterly dividend.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.84 elevated, pricing in significant growth expectations. Forward P/E 23.1x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.3B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.84 |
| Forward P/E | 23.1 |
| Current P/E | 25.2 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.5% to -3.8% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.8pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-1.07), momentum weakening. RSI neutral at 49.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.75% (CS: 28) | Weak |
| RSI_14 | 49.3 | Neutral |
| MACD Histogram | -1.07 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.080x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $257.27
- **Stop Loss:** $247.09 (4.0% risk)
- **Target:** $267.45 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $7,460.83
- **Portfolio %:** 7.46%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*